Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.

ABSTRACT:

Background

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now permit randomized, controlled trials of shortened-duration, all-oral treatments for rifampin-resistant tuberculosis.

Methods

We conducted a phase 3, multinational, open-label, randomized, controlled noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis with five 9-month oral regimens that included various combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). Participants were randomly assigned (with the use of Bay

SUBMITTER: Guglielmetti L 

PROVIDER: S-EPMC7617355 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature